mva/hiv62b
Vaccineexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04041674)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04041674 | Phase 1 | Sep 30, 2019 | Duke University, GeoVax, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of Maryland, University of Rochester, University of Washington, Vanderbilt University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| GeoVax, Inc. | For profit | 1 | 0 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2019 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1